$SSKN
STRATA Skin Sciences, Inc.

2021 Q3 Form 10-Q Financial Statement

#000114036121028479 Filed on August 16, 2021

View on sec.gov

Income Statement

Concept 2021 Q3 2021 Q2 2020 Q4
Revenue $7.711M $7.382M $6.720M
YoY Change 37.38% 83.18% -24.49%
Cost Of Revenue $2.335M $2.621M $2.180M
YoY Change -2.01% 26.86% -21.3%
Gross Profit $5.376M $4.761M $4.540M
YoY Change 66.44% 142.41% -25.94%
Gross Profit Margin 69.72% 64.49% 67.56%
Selling, General & Admin $5.470M $5.281M $4.570M
YoY Change 37.44% 58.49% -23.45%
% of Gross Profit 101.75% 110.92% 100.66%
Research & Development $371.0K $403.0K $320.0K
YoY Change -9.73% 63.16% 52.38%
% of Gross Profit 6.9% 8.46% 7.05%
Depreciation & Amortization $575.0K $520.0K $800.0K
YoY Change 26.65% 5.05% -24.53%
% of Gross Profit 10.7% 10.92% 17.62%
Operating Expenses $5.841M $5.684M $4.890M
YoY Change 33.02% 58.82% -21.0%
Operating Profit -$465.0K -$923.0K -$350.0K
YoY Change -59.95% -42.85% 483.33%
Interest Expense -$52.00K $26.00K -$20.00K
YoY Change 160.0% -230.0% -75.0%
% of Operating Profit
Other Income/Expense, Net -$52.00K $2.009M
YoY Change 147.62% -11261.11%
Pretax Income -$517.0K $1.086M -$380.0K
YoY Change -56.26% -166.5% -30.91%
Income Tax $4.000K $4.000K $70.00K
% Of Pretax Income 0.37%
Net Earnings -$521.0K $1.082M -$440.0K
YoY Change -58.45% -164.4% -15.38%
Net Earnings / Revenue -6.76% 14.66% -6.55%
Basic Earnings Per Share -$0.02 $0.03
Diluted Earnings Per Share -$15.26K $0.03 -$13.02K
COMMON SHARES
Basic Shares Outstanding 34.02M 33.88M 33.77M
Diluted Shares Outstanding 34.15M 34.32M

Balance Sheet

Concept 2021 Q3 2021 Q2 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $13.05M $9.576M $10.60M
YoY Change 17.97% -14.73% 30.38%
Cash & Equivalents $13.05M $9.576M $10.60M
Short-Term Investments
Other Short-Term Assets $623.0K $7.983M $7.840M
YoY Change -92.07% 1.95% -2.12%
Inventory $3.225M $3.049M $3.444M
Prepaid Expenses
Receivables $3.151M $2.854M $2.944M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $20.05M $23.46M $24.83M
YoY Change -19.61% -1.79% 5.42%
LONG-TERM ASSETS
Property, Plant & Equipment $6.403M $5.931M $5.529M
YoY Change 21.78% 18.64% 2.98%
Goodwill $8.803M $8.803M
YoY Change 0.0% 0.0%
Intangibles $5.640M $6.345M
YoY Change -20.0% -20.24%
Long-Term Investments
YoY Change
Other Assets $233.0K $249.0K $282.0K
YoY Change -21.81% -20.7% -18.73%
Total Long-Term Assets $26.71M $21.44M $21.95M
YoY Change 20.72% -3.96% -7.74%
TOTAL ASSETS
Total Short-Term Assets $20.05M $23.46M $24.83M
Total Long-Term Assets $26.71M $21.44M $21.95M
Total Assets $46.76M $44.90M $46.78M
YoY Change -0.65% -2.84% -1.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.480M $2.642M $2.764M
YoY Change -28.9% 7.79% 47.02%
Accrued Expenses $5.548M $5.101M $4.690M
YoY Change 21.72% 8.46% -8.65%
Deferred Revenue $2.375M $2.262M
YoY Change 132.84% -20.13%
Short-Term Debt $0.00 $7.275M $7.280M
YoY Change -100.0% -0.07% 0.0%
Long-Term Debt Due $0.00 $3.000K $1.478M
YoY Change -100.0% -99.62%
Total Short-Term Liabilities $12.15M $17.78M $18.84M
YoY Change -34.94% 7.1% 8.05%
LONG-TERM LIABILITIES
Long-Term Debt $7.282M $497.0K $1.050M
YoY Change 422.38% -71.26%
Other Long-Term Liabilities $873.0K $49.00K $34.00K
YoY Change 1578.85% -30.99% -80.9%
Total Long-Term Liabilities $8.155M $546.0K $1.084M
YoY Change 463.97% -69.67% 508.99%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.15M $17.78M $18.84M
Total Long-Term Liabilities $8.155M $546.0K $1.084M
Total Liabilities $20.58M $19.10M $20.89M
YoY Change -2.66% -1.71% 11.75%
SHAREHOLDERS EQUITY
Retained Earnings -$220.3M -$219.0M
YoY Change 1.4% 2.06%
Common Stock $34.00K $34.00K
YoY Change 0.0% 3.03%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.18M $25.80M $25.89M
YoY Change
Total Liabilities & Shareholders Equity $46.76M $44.90M $46.78M
YoY Change -0.65% -2.84% -1.19%

Cashflow Statement

Concept 2021 Q3 2021 Q2 2020 Q4
OPERATING ACTIVITIES
Net Income -$521.0K $1.082M -$440.0K
YoY Change -58.45% -164.4% -15.38%
Depreciation, Depletion And Amortization $575.0K $520.0K $800.0K
YoY Change 26.65% 5.05% -24.53%
Cash From Operating Activities $452.0K $237.0K $350.0K
YoY Change -17.82% -60.5% -68.47%
INVESTING ACTIVITIES
Capital Expenditures -$1.057M -$726.0K -$710.0K
YoY Change 46.81% 458.46% -49.65%
Acquisitions
YoY Change
Other Investing Activities -$3.473M
YoY Change
Cash From Investing Activities -$4.530M -$726.0K -$710.0K
YoY Change 529.17% 458.46% -49.65%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 92.00K 0.000 20.00K
YoY Change -100.0% -106.67%
NET CHANGE
Cash From Operating Activities 452.0K 237.0K 350.0K
Cash From Investing Activities -4.530M -726.0K -710.0K
Cash From Financing Activities 92.00K 0.000 20.00K
Net Change In Cash -3.986M -489.0K -340.0K
YoY Change 2244.71% -116.3% -43.33%
FREE CASH FLOW
Cash From Operating Activities $452.0K $237.0K $350.0K
Capital Expenditures -$1.057M -$726.0K -$710.0K
Free Cash Flow $1.509M $963.0K $1.060M
YoY Change 18.82% 31.92% -57.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001051514
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10604000
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33889239
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33889239
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33801045
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33801045
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
34000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
34000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7382000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
2066000
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2028000
CY2020Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2009000
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-18000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1680000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2020Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2020Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33876568
CY2020Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33731739
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34318495
CY2020Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33731739
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13209000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10760000
us-gaap Cost Of Revenue
CostOfRevenue
4735000
us-gaap Cost Of Revenue
CostOfRevenue
4397000
CY2021Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
274000
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2854000
CY2021Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
206000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
2944000
CY2021Q2 us-gaap Inventory Net
InventoryNet
3049000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3444000
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
526000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
331000
CY2021Q2 us-gaap Assets Current
AssetsCurrent
23462000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
24831000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5931000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5529000
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
814000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
988000
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5640000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6345000
CY2021Q2 us-gaap Goodwill
Goodwill
8803000
CY2020Q4 us-gaap Goodwill
Goodwill
8803000
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
249000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2764000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5101000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4690000
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
383000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
369000
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
17779000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18838000
CY2021Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
497000
CY2021Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
262000
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
254000
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
513000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
710000
CY2021Q2 us-gaap Liabilities
Liabilities
19100000
CY2020Q4 us-gaap Liabilities
Liabilities
20886000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.10
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
244831000
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-220309000
CY2021Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2642000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1050000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
25892000
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44899000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46778000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
25799000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
174000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
159000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-158000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2953000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-68000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
72000
us-gaap Share Based Compensation
ShareBasedCompensation
1243000
us-gaap Share Based Compensation
ShareBasedCompensation
840000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
8000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
135000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-395000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
443000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
162000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-116000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-122000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
571000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
411000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-431000
sskn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-183000
sskn Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-142000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
387000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1201000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
97000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1466000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-730000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1079000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2999000
us-gaap Net Income Loss
NetIncomeLoss
-2715000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17033000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18628000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9576000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11231000
CY2021Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
7457000
CY2020Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
7397000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17033000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18628000
us-gaap Interest Paid Net
InterestPaidNet
57000
us-gaap Interest Paid Net
InterestPaidNet
103000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15629000
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
0-51481
dei Entity Registrant Name
EntityRegistrantName
STRATA SKIN SCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-3986004
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Walnut Grove Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 140
dei Entity Address City Or Town
EntityAddressCityOrTown
Horsham
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19044
dei City Area Code
CityAreaCode
215
dei Local Phone Number
LocalPhoneNumber
619-3200
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
SSKN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
34017612
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9576000
CY2021Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
7457000
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
7508000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
282000
CY2021Q2 us-gaap Assets
Assets
44899000
CY2020Q4 us-gaap Assets
Assets
46778000
CY2021Q2 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
7275000
CY2020Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
7275000
CY2021Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
3000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1478000
CY2021Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2375000
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
2262000
CY2021Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
49000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
34000
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
246074000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-218973000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4030000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
2621000
CY2021Q2 us-gaap Gross Profit
GrossProfit
4761000
CY2020Q2 us-gaap Gross Profit
GrossProfit
1964000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
403000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
247000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3160000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1442000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2121000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1890000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5684000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
3579000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-923000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1615000
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-19000
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-18000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1086000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1633000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1082000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
430000
CY2020Q1 sskn Conversion Of Convertible Preferred Stock Amount
ConversionOfConvertiblePreferredStockAmount
0
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1035000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
28048000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
410000
CY2020Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1680000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
26778000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
25892000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
662000
CY2021Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-2418000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
24136000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
581000
CY2021Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
0
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
1082000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
25799000
us-gaap Net Income Loss
NetIncomeLoss
-1336000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1706000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1986000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
15000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-107000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
113000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1812000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0
us-gaap Gross Profit
GrossProfit
8474000
us-gaap Gross Profit
GrossProfit
6363000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
787000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
539000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6092000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4395000
sskn Impairment Of Lasers Placed In Service
ImpairmentOfLasersPlacedInService
19000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2028000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
sskn Payment For Lasers Placed In Service Net
PaymentForLasersPlacedInServiceNet
1369000
sskn Payment For Lasers Placed In Service Net
PaymentForLasersPlacedInServiceNet
730000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33839554
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33448030
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33839554
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33448030
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
28653000
sskn Impairment Of Lasers Placed In Service
ImpairmentOfLasersPlacedInService
63000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4910000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3992000
us-gaap Operating Expenses
OperatingExpenses
11789000
us-gaap Operating Expenses
OperatingExpenses
8926000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3315000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2563000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2028000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-41000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-17000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1987000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1328000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2580000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
135000
us-gaap Net Income Loss
NetIncomeLoss
-1336000
us-gaap Net Income Loss
NetIncomeLoss
-2715000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
2528000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2528000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
18112000
CY2021Q2 sskn Delayed Payment To Vendors
DelayedPaymentToVendors
472000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6437147
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Reclassifications</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Certain reclassifications from the prior year presentation have been made to conform to the current year presentation. These reclassifications did not have a material impact on the Company’s equity, results of operations, or cash flows.</div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align: justify; font-style: italic; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Use of Estimates</div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported of assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting periods. Actual results could differ from those estimates and be based on events different from those assumptions. As of June 30, 2021, the more significant estimates include (1) revenue recognition, in regards to deferred revenues and the contract term and valuation allowances of accounts receivable, (2) the inputs used in the impairment analyses of goodwill, (3) the estimated useful lives of intangible assets and property and equipment, (4) the inputs used in determining the fair value of equity-based awards, (5) the valuation allowance related to deferred tax assets, (6) the inventory reserves, (7) state sales and use tax accruals and (8) warranty claims.</div> <div><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;"> </span></div> <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">Additionally, the full impact of the ongoing COVID-19 outbreak is unknown and cannot be reasonably estimated. However, management has made appropriate accounting estimates on certain accounting matters, which include the allowance for doubtful accounts, inventory valuation, carrying value of the goodwill and other long-lived assets, based on the facts and circumstances available as of the reporting date. The Company’s future assessment of the magnitude and duration of the ongoing COVID-19 outbreak, as well as other factors, could result in material impacts to the Company’s financial statements in future reporting periods.</div>
CY2021Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5365521
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5756838
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5791899
CY2021Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
51000
CY2021Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q2 sskn Contract With Customer Liability Current Advance Consideration
ContractWithCustomerLiabilityCurrentAdvanceConsideration
51000
CY2021Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P36M
CY2021Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
69000
CY2021Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
18000
CY2021Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
20000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
54000
CY2020Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
53000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
110000
CY2021Q2 sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-186000
sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-343000
CY2020Q2 sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-86000
sskn Co Pay Reimbursements Recorded As Reduction Of Revenue
CoPayReimbursementsRecordedAsReductionOfRevenue
-254000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7382000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13209000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4030000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10760000
CY2021Q2 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2877000
CY2020Q4 us-gaap Inventory Work In Process And Raw Materials
InventoryWorkInProcessAndRawMaterials
2949000
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
172000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
495000
CY2021Q2 us-gaap Inventory Net
InventoryNet
3049000
CY2020Q4 us-gaap Inventory Net
InventoryNet
3444000
CY2021Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24676000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23374000
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18745000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17845000
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5931000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5529000
CY2021Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
520000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1001000
CY2020Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
495000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1081000
CY2021Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
16100000
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10460000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5640000
CY2021Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
353000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
705000
CY2020Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
453000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
905000
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
705000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1410000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1410000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1410000
CY2021Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
705000
CY2021Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
5640000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
87000
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1336000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
891000
CY2021Q2 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
3154000
CY2020Q4 us-gaap Sales And Excise Tax Payable Current
SalesAndExciseTaxPayableCurrent
3105000
CY2021Q2 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
544000
CY2021Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
67000
CY2020Q4 sskn Accrued Professional Fees Other Accrued Liabilities
AccruedProfessionalFeesOtherAccruedLiabilities
607000
CY2021Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5101000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4690000
CY2021Q2 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
171000
CY2021Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
85000
CY2020Q1 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
181000
CY2020Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
113000
CY2019Q4 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
232000
CY2021Q2 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
36000
CY2020Q2 us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
6000
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
40000
us-gaap Product Warranty Accrual Period Increase Decrease
ProductWarrantyAccrualPeriodIncreaseDecrease
9000
CY2021Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
23000
CY2020Q2 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
48000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
55000
us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
102000
CY2021Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
98000
CY2020Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
139000
CY2021Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
98000
CY2020Q2 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
139000
CY2021Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
67000
CY2020Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
119000
CY2021Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
67000
CY2020Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
119000
CY2021Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
31000
CY2020Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
20000
CY2021Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
31000
CY2020Q2 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
20000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
581000
us-gaap Share Based Compensation
ShareBasedCompensation
1243000
CY2020Q2 us-gaap Share Based Compensation
ShareBasedCompensation
410000
us-gaap Share Based Compensation
ShareBasedCompensation
840000
CY2021Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2641000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P1Y3M10D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
173000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
4000
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
47000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
135000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7382000
CY2021Q2 us-gaap Cost Of Revenue
CostOfRevenue
2621000
CY2021Q2 us-gaap Gross Profit
GrossProfit
4761000
CY2021Q2 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.645
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
403000
CY2021Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3160000
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2121000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
5684000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-923000
CY2021Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2028000
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-19000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1086000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13209000
us-gaap Cost Of Revenue
CostOfRevenue
4735000
us-gaap Gross Profit
GrossProfit
8474000
sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.642
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
787000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6092000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4910000
us-gaap Operating Expenses
OperatingExpenses
11789000
us-gaap Operating Income Loss
OperatingIncomeLoss
-3315000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
2028000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-41000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1328000
CY2020Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4030000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
2066000
CY2020Q2 us-gaap Gross Profit
GrossProfit
1964000
CY2020Q2 sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.487
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
247000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1442000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1890000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
3579000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1615000
CY2020Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-18000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1633000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10760000
us-gaap Cost Of Revenue
CostOfRevenue
4397000
us-gaap Gross Profit
GrossProfit
6363000
sskn Percentage Of Gross Profit
PercentageOfGrossProfit
0.591
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
539000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4395000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3992000
us-gaap Operating Expenses
OperatingExpenses
8926000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2563000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-17000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2580000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
174000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
159000
CY2021Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
107000
us-gaap Operating Lease Cost
OperatingLeaseCost
223000
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
112000
us-gaap Operating Lease Cost
OperatingLeaseCost
224000
CY2020Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
115000
CY2021Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
115000
us-gaap Operating Lease Payments
OperatingLeasePayments
231000
us-gaap Operating Lease Payments
OperatingLeasePayments
231000
sskn Operating Lease Incremental Borrowing Rate Percent
OperatingLeaseIncrementalBorrowingRatePercent
0.0976
CY2021Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
239000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
371000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
242000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
186000
CY2021Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1038000
CY2021Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
142000
CY2021Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
896000

Files In Submission

Name View Source Status
R46.htm Edgar Link pending
0001140361-21-028479-index-headers.html Edgar Link pending
0001140361-21-028479-index.html Edgar Link pending
0001140361-21-028479.txt Edgar Link pending
0001140361-21-028479-xbrl.zip Edgar Link pending
brhc10027916_10q.htm Edgar Link pending
brhc10027916_10q_htm.xml Edgar Link completed
brhc10027916_ex31-1.htm Edgar Link pending
brhc10027916_ex31-2.htm Edgar Link pending
brhc10027916_ex32-1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image00002.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
sskn-20210630.xsd Edgar Link pending
sskn-20210630_cal.xml Edgar Link unprocessable
sskn-20210630_def.xml Edgar Link unprocessable
sskn-20210630_lab.xml Edgar Link unprocessable
sskn-20210630_pre.xml Edgar Link unprocessable